drugset / Trial / NCT05242484
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.
Timeline
- Start
- 2022-09-19
- Primary completion
- 2025-05-15
- Completion
- 2029-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golimumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Guselkumab | Monoclonal antibody | — | Subcutaneous |
| Subject | JNJ-78934804 | Unknown | — | Subcutaneous |